The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease

International Journal of COPD

Volumn 8, Issue , 2013, Pages 53-64

  Decramer, Marc L ^a   Hanania, Nicola A ^b   Lötvall, Jan O ^c   Yawn, Barbara P ^d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d OLMSTED MEDICAL CENTER   (United States)

Author keywords

Bronchodilator; COPD; Formoterol; Indacaterol; LABA; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; INDACATEROL; LONG ACTING DRUG; PLACEBO; SALMETEROL;

BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HUMAN; ISCHEMIA; MORTALITY; MUSCLE SPASM; POTASSIUM BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TACHYCARDIA; TREMOR;

BRONCHODILATOR; COPD; FORMOTEROL; INDACATEROL; LABA; SALMETEROL;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; BLOOD GLUCOSE; COUGH; ETHANOLAMINES; HEADACHE; HUMANS; INDANS; NASOPHARYNGITIS; POTASSIUM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RESPIRATORY TRACT INFECTIONS; SPASM; TACHYCARDIA; TREMOR;

EID: 84873342637     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S39018     Document Type: Review

References (82)

1. Centers for Disease Control and Prevention. Deaths: preliminary data for 2009. National Vital Statistics Reports. 2011;59(4). Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_04.pdf. Accessed September 28, 2012.
2. World Health Organization (WHO). Chronic respiratory diseases: chronic obstructive pulmonary disease [web page on the Internet]. Geneva: WHO Chronic Diseases and Health Promotion Department; nd. Available from: http://www.who.int/respiratory/copd/en/. Accessed December 3, 2012.
3. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(2): 180-184.
4. O'Donnell DE. Dynamic lung hyperinflation and its clinical implication in COPD. Rev Mal Respir. 2008;25(10):1305-1318. French.
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Rev ed. GOLD; 2011. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf. Accessed June 14, 2012.
6. Norris SL, Yen PY, Dana TL, Care BR, Burda BU. Drug Class Review: Beta2-agonists. Portland, OR: Oregon Health and Science University; 2006. Available from: http://www.ncbi.nlm.nih.gov/books/NBK10429/. Accessed September 28, 2012.
7. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
8. Calverley PM. New options for bronchodilator treatment in COPD. Thorax. 2010;65(6):468-469.
9. Hanania NA, Sharafkhaneh A, Celli B, et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011;12:6.
10. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
11. O'Donnell DE, Webb KA. The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol. 2008;105(2): 753-755; discussion 755-757.
12. Brienza NS, Amor-Carro O, Ramos-Barbón D. An update on the use of indacaterol in patients with COPD. Ther Adv Respir Dis. 2011;5(1): 29-40.
13. Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008;133(5): 1079-1087.
14. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149.
15. Allen and Hanburys Ltd. Serevent Accuhaler [summary of product characteristics]. electronic Medicines Compendium (eMC); updated May 17, 2012. Available from: http://www.medicines.org.uk/EMC/medicine/91/SPC/Serevent+Accuhaler/. Accessed September 11, 2012.
16. Allen and Hanburys Ltd. Serevent Diskus [summary of product characteristics]. eMC; updated May 17, 2012. Available from: http://www.medicines.org.uk/EMC/medicine/92/SPC/Serevent+Diskhaler/. Accessed September 11, 2012.
17. Allen and Hanburys Ltd. Serevent Evohaler [summary of product characteristics]. eMC; updated May 24, 2012. Available from: http://www.medicines.org.uk/EMC/medicine/17201/SPC/Serevent+Evohaler/. Accessed September 11, 2012.
18. Novartis Pharmaceuticals UK Ltd. Foradil [summary of product characteristics]. Available from: http://www.medicines.org.uk/EMC/medicine/1286/SPC/Foradil/. eMC; updated October 12, 2012. Accessed September 11, 2012.
19. Novartis Pharmaceuticals UK Ltd. Onbrez Breezhaler 150 and 300 microgram inhalation powder, hard capsules [summary of product characteristics]. eMC; updated August 14, 2012. Available from: http://www.medicines.org.uk/EMC/searchresults.aspx?term=onbrez. Accessed September 11, 2012.
20. Price DB, Yawn BP, Jones RC. Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. Mayo Clin Proc. 2010;85(12):1122-1129.
21. Blanchette CM, Berry SR, Lane SJ. Advances in chronic obstructive pulmonary disease among older adults. Curr Opin Pulm Med. 2011;17(2):84-89.
22. Lange P, Scharling H, Ulrik CS, Vestbo J. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax. 2006;61(2):100-104.
23. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. NIH Publication No 02-3659. Bethesda, MD: National Institutes of Health; 1995 [updated 2005]. Available from: http://www.ginasthma.org/pdf/archived/GINAWorkshop05Clean.pdf. Accessed June 14, 2012.
24. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26.
25. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J. 2009;33(1):21-32.
26. Beasley R, Martinez FD, Hackshaw A, et al. Safety of long-acting beta-agonists: urgent need to clear the air remains. Eur Respir J. 2009;33(1):3-5.
27. US Food and Drug Administration (FDA). FDA Drug Safety Communication: Drug labels now contain updated recommendations on the appropriate use of long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs) [web page on the Internet]. Silver Spring, MD: FDA; updated April 15, 2011. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213836.htm. Accessed September 28, 2012.
28. Jenkins CR, Celli B, Anderson JA, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012;39(1):38-45.
29. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956-962.
30. Dal Negro RW, Pomari C, Tognella S, Micheletto C. Salmeterol and fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther. 2003;16(4):241-246.
31. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912-919.
32. Kliber A, Lynd LD, Sin DD. The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir Res. 2010;11:56.
33. Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:477-492.
34. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149(6):380-390.
35. Mapel DW, Nelson LS, Lydick E, Soriano J, Yood MU, Davis KJ. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. COPD. 2007;4(2):127-134.
36. Wang J, Nie B, Xiong W, Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther. 2012;37(2):204-211.
37. Calverley PM, Anderson JA, Celli B, et al; TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719-725.
38. Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105(4):571-579.
39. Dahl R, Chung KF, Buhl R, et al; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473-479.
40. Kornmann O, Dahl R, Centanni S, et al; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2): 273-279.
41. Donohue JF, Fogarty C, Lötvall J, et al; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2): 155-162.
42. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B; INDORSE Study Investigators. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140(1):68-75.
43. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100(1):115-122.
44. Insulander P, Juhlin-Dannfelt A, Freyschuss U, Vallin H. Electrophysiologic effects of salbutamol, a beta2-selective agonist. J Cardiovasc Electrophysiol. 2004;15(3):316-322.
45. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309-2321.
46. Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs. 2005;65(12):1595-1610.
47. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012;142(2):305-311.
48. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176(2):162-166.
49. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012;67(12):1075-1080.
50. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138.
51. Cazzola M, MacNee W, Martinez FJ, et al; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416-469.
52. Lambert RK, Wiggs BR, Kuwano K, Hogg JC, Pare PD. Functional significance of increased airway smooth muscle in asthma and COPD. J Appl Physiol. 1993;74(6):2771-2781.
53. Mcivor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med. 1998;158(3):924-930.
54. Lipworth BJ. Antagonism of long-acting beta2-adrenoceptor agonism. Br J Clin Pharmacol. 2002;54(3):231-245.
55. O'Donnell DE. Is sustained pharmacologic lung volume reduction now possible in COPD? Chest. 2006;129(3):501-503.
56. McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett SB. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest. 2003;112(4):619-626.
57. Nguyen LP, Lin R, Parra S, et al. Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A. 2009;106(7):2435-2440.
58. Hanania NA, Singh S, El-Wali R, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008;21(1):134-141.
59. Lipworth BJ, Williamson PA. Beta blockers for asthma: a double-edged sword. Lancet. 2009;373(9658):104-105.
60. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet. 2010;376(9743):803-813.
61. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19-26.
62. Vogelmeier C, Hederer B, Glaab T, et al; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093-1103.
63. Wedzicha J, Decramer M, Seemungal T. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J. Epub July 26, 2012.
64. Tiengo A, Fadini GP, Avogaro A. The metabolic syndrome, diabetes and lung dysfunction. Diabetes Metab. 2008;34(5):447-454.
65. Rabe KF. Treating COPD - the TORCH trial, P values, and the Dodo. N Engl J Med. 2007;356(8):851-854.
66. La Vecchia C, Fabbri LM. Prevention of death in COPD. N Engl J Med. 2007;356(21):2211-2212.
67. Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008;31(5):927-933.
68. Rossi A, Kristufek P, Levine BE, et al; Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002;121(4):1058-1069.
69. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74-81.
70. Campbell M, Eliraz A, Johansson G, et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med. 2005;99(12):1511-1520.
71. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975-2000.
72. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102(11): 1511-1520.
73. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549-565.
74. Doherty DE, Tashkin DP, Kerwin E, et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:57-71.
75. Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial. Int J Chron Obstruct Pulmon Dis. 2012;7:43-55.
76. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(8):1084-1091.
77. Chapman KR, Arvidsson P, Chuchalin AG, et al; International study group. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. Can Respir J. 2002;9(3): 178-185.
78. Calverley P, Pauwels R, Vestbo J, et al; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449-456.
79. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58(5):399-404.
80. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124(3):834-843.
81. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax. 2006;61(2): 122-128.
82. FDA. FDA Pulmonary-allergy Drugs Advisory Committee Meeting September 6, 2002: Spiriva® (tiotropium bromide) Inhalation Powder. NDA 21-395. Silver Spring, MD: FDA; 2002. Available from: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3890B1_01_Boehringer%20Ingelheim.pdf. Accessed April 30, 2012.